AlphAIAlphAI — Financial news for AI agents
finance.biggo.comOCT 133 min read$MRK

Keytruda SC Hits 16% Conversion Rate One Year After U.S. Launch, Outpacing Opdivo and Tecentriq

Merck's Keytruda SC, a subcutaneous formulation of its cancer drug Keytruda, reached a 16% conversion rate in the U.S. one year after launch, outpacing competitors Opdivo and Tecentriq. September U.S. sales were $324 million, 15.8% of total Keytruda sales. UBS estimates Alteogen, which provides the technology, could earn $50 million in milestone payments. European sales are restricted due to patent disputes, but U.S. sales are projected to reach $5 billion by 2027.

Original reporting
finance.biggo.com
Published Oct 13, 2026, 12:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$MRK
Bullish
high confidence
Mentioned
$MRK
Relevance
7/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$MRKBullishMed
01

Why it matters

The conversion rate and sales figures suggest a new revenue stream for Merck and royalty income for partner Alteogen.

02

Market read

First report of Keytruda SC's conversion performance provides fresh catalyst for Merck's stock and biotech sector sentiment.

03

What to watch

Milestone payments are estimates; actual cash may differ if contractual thresholds are not met.

Relevance 7/10Novelty 7/10Timing: today

Background

Keytruda SC, Merck's subcutaneous immunotherapy, shows rapid adoption in the U.S., outpacing rivals Opdivo SC and Tecentriq SC.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck's Keytruda SC conversion rate reached 16% one year after U.S. launch, driving $324M September sales and $50M milestone payment estimate.

Expected impact

likely upside as higher conversion drives incremental revenue and milestone payments.

Evidence & confidence

US sales growth and milestone estimates are new, material data that can boost investor sentiment.

Market effects

Sector

Strengthens outlook for immuno‑oncology and biotech sector as subcutaneous formulations gain market share.

Regional

Boosts U.S. biotech exposure; limited impact on European markets due to patent dispute.

Global

Highlights Merck's growth engine and potential royalty income for partner Alteogen.

Counterpoint

What could challenge this read

European patent injunction could slow global rollout, tempering long‑term upside.

Key entities

  • company
    Merck & Co.

    Manufacturer of Keytruda SC, ticker MRK.

  • company
    Alteogen

    Korean biotech partner receiving milestone payments.

Read at source← All news

Related articles

OCT 13
$MRKLow

Merck appoints Paul Diaz to board of directors

Merck & Co. (NYSE:MRK) announced Paul J. Diaz, managing partner at Cressey & Company, will join its board of directors effective November 1, 2026. Diaz will stand for election by shareholders in May 2027, expanding the board to 14 members. He brings healthcare industry leadership experience from roles at Myriad Genetics and Kindred Healthcare.

investing.com1 min
OCT 13
$MRKMed

Merck will present melanoma data showing its combination improved survival without cancer returning or spreading.

Merck (MRK) will present data from three Phase 3 trials at ESMO 2026. INTerpath-001 shows improved survival for melanoma patients using intismeran autogene plus KEYTRUDA. TroFuse-005 shows sacituzumab tirumotecan improves survival for certain endometrial cancer patients. KEYNOTE-C93 suggests KEYTRUDA monotherapy benefits certain endometrial cancer patients. Merck will hold an investor event on October 26.

stocktitan.net2 min
OCT 12
$MRKMed

Jefferies cuts Merck’s remigromig sales forecast after eye-disease trial raises concerns

Jefferies reduced its peak sales forecast for Merck's experimental eye treatment remigromig by 60% to $300M after trial results showed concerns about efficacy and safety compared to Lucentis. The drug met non-inferiority thresholds but showed smaller vision improvements and higher safety risks. Jefferies lowered its price target for Merck to $176 but maintained a buy rating.

finance.yahoo.com6 min
OCT 12
$MRKHigh

RBC Capital cuts Merck stock price target on lower 2027 earnings outlook

RBC Capital reduced its price target for Merck (NYSE:MRK) to $145 from $150, citing lower 2027 earnings expectations. The firm's 2026 estimates align with consensus, but it forecasts slower 2027 revenue growth. Other analysts have mixed views, with Guggenheim maintaining a Buy rating and Cantor Fitzgerald raising its target. Merck also faces legal challenges and pipeline updates.

investing.com2 min
OCT 12
$MRKMed

Merck publishes one-year results

Merck reported one-year trial results for Remigromig, showing it met primary endpoints by demonstrating noninferiority to Ranibizumab in improving visual acuity. The drug had a higher incidence of adverse events related to proliferative diabetic retinopathy, which the company said were manageable and could reflect disease progression. Additional analyses are ongoing.

marketscreener.com1 min
OCT 12
$MRKMedAI 8/10

Personalized mRNA vaccines are poised to revolutionize cancer treatments. Here are the barriers.

Merck and Moderna's personalized mRNA melanoma vaccine, intismeran autogene, met phase 3 trial endpoints. Production challenges include scaling tiny batches and cost. Moderna's facility began clinical supply in 2025, targeting 6-8 weeks from biopsy to dose. Provenge's high manufacturing cost led to bankruptcy, serving as a cautionary tale. Standalone personalized vaccines show mixed results, with a recent trial halted due to survival imbalance.

geneticliteracyproject.org2 min